Nektar Therapeutics Stock Price, News & Analysis

Nektar Therapeutics (NKTR) has agreed to sell its Huntsville, Alabama manufacturing facility and PEGylation reagent supply business to Ampersand Capital Partners for $90 million, consisting of $70 million in cash and $20 million in equity ownership in the new portfolio company. The 124,000-square-foot facility will become a standalone company under Ampersand, with all current employees being offered positions. The strategic sale allows Nektar to streamline operations and focus on immunology R&D programs while extending its cash runway into Q4 2026. The deal includes supply agreements for Nektar's PEG reagent needs and is expected to close by December 2, 2024.

Nektar Therapeutics (NKTR) has scheduled its Q3 2024 financial results announcement for Thursday, November 7, 2024, after U.S. market close. CEO Howard Robin will host a conference call at 5:00 p.m. ET/2:00 p.m. PT to discuss the results. The press release and audio webcast will be accessible through the company's website, with the webcast replay available until December 7, 2024. Pre-registration is required for conference call access.

Nektar Therapeutics (NKTR) published peer-reviewed data from two Phase 1b studies in Nature Communications showing promising results for rezpegaldesleukin in treating atopic dermatitis (AD) and psoriasis (PsO). The studies demonstrated that the drug safely increased regulatory T cells (Tregs) and improved disease outcomes, with effects lasting up to 36 weeks after treatment cessation. High-dose AD patients showed an 83% improvement in EASI score after 12 weeks, with EASI-75 and vIGA-AD responses maintained in 71% and 80% of week 12 responders respectively for 36 weeks post-treatment.

Nektar Therapeutics (Nasdaq: NKTR) has published Phase 1 data in Blood for its novel IL-15 agonist NKTR-255 combined with autologous CD19-22 CAR-T cell therapy in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL). The study showed:

• 89% of patients (8 out of 9) achieved measurable residual disease (MRD) negative remission
• 67% relapse-free/progression-free survival at 12 months, double that of historical controls (38%)
• No dose-limiting toxicities related to NKTR-255
• Significant increases in proinflammatory cytokines and chemokines, suggesting lymphocyte trafficking to tissues

The combination therapy showed promising efficacy in relapsed or refractory B-ALL patients, with potential to improve durability of CAR-T cell therapies.

Nektar Therapeutics announced multiple presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology Congress. New proteomic analyses show that REZPEG increases immune-regulating pathways while reducing specific serum proteins elevated in atopic dermatitis patients. REZPEG is a novel regulatory T cell stimulator designed to address immune system imbalance in autoimmune disorders.

Two Phase 2b studies are ongoing: one in moderate-to-severe atopic dermatitis and another in severe to very severe alopecia areata. Topline data is expected in the first half of 2025 for the AD study and mid-2025 for the AA study. The presentations highlighted REZPEG's unique proteomic profile, its effect on immunoregulatory pathways, and its potential to offer durable effects and long-term remission in atopic dermatitis treatment.

Nektar Therapeutics (NKTR) has announced its management's participation in two upcoming investor conferences. The first is the H.C. Wainwright 26th Annual Global Investment Conference in New York City on September 9, 2024 at 3:00 p.m. ET. The second is the Stifel Virtual Immunology and Inflammation Summit on September 17, 2024 at 12:30 p.m. ET.

Both presentations will be accessible via webcast through the Investor Events section of Nektar's website. The webcasts will remain available for replay until October 9, 2024 and October 17, 2024, respectively, allowing investors and interested parties to access the information even after the live events.

Nektar Therapeutics (NKTR) reported Q2 2024 financial results with revenue of $23.5 million, up from $20.5 million in Q2 2023. The company's cash position was $290.6 million as of June 30, 2024, expected to support operations into Q3 2026. Net loss for Q2 2024 was $52.4 million or $0.25 per share. Nektar is progressing with Phase 2 studies of rezpegaldesleukin in atopic dermatitis and alopecia areata, with topline data expected in H1 and mid-2025, respectively. The company is also advancing NKTR-0165, a TNFR2 agonist antibody, towards IND submission in mid-2025. Recent data on NKTR-255 in combination with CAR-T therapy showed promising results in B-cell acute lymphoblastic leukemia patients.

Nektar Therapeutics (Nasdaq: NKTR) has announced that it will release its financial results for the second quarter of 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. The company's President and CEO, Howard Robin, will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time to review the results.

Investors and interested parties can access the press release and live audio-only webcast of the conference call through a link on the Home Page and Investors section of Nektar's website. The web broadcast will be available for replay until September 8, 2024. To participate in the conference call, pre-registration is required through the Nektar Earnings Call Registration link.

Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associated with various autoimmune diseases like ulcerative colitis and vitiligo. Preclinical studies revealed that NKTR-0165 enhances Treg cell function, a key component in immune response regulation, without affecting TNFR1 signaling. IND-enabling studies are ongoing, with human trials expected in the first half of 2025.